What is the recommended dosing, contraindications, and monitoring for desidustat in adults with anemia due to chronic kidney disease?

Desidustat for Anemia in Chronic Kidney Disease

Desidustat is an oral HIF-prolyl hydroxylase inhibitor approved in India for treating anemia in adults with CKD (both dialysis-dependent and non-dialysis-dependent), with a standard starting dose of 100 mg three times weekly, titrated to maintain hemoglobin levels of 10-12 g/dL. 1, 2, 3

Dosing Recommendations

Starting Dose and Titration

• Initial dose: 100 mg orally three times weekly for both dialysis-dependent and non-dialysis-dependent CKD patients 2, 3
• Titrate dose to maintain target hemoglobin of 10-12 g/dL 3
• Administer in fasting conditions for optimal absorption 4
• Dose adjustments should be made based on hemoglobin response during the evaluation period (weeks 16-24) 2, 3

Efficacy Data

• In non-dialysis CKD patients: Mean hemoglobin increase of 1.95 g/dL from baseline to weeks 16-24, with 77.78% achieving hemoglobin response (≥1 g/dL increase) 2
• In dialysis-dependent CKD patients: Mean hemoglobin increase of 0.95 g/dL from baseline to weeks 16-24, with 59.22% achieving hemoglobin response 3
• Phase 2 dose-ranging studies showed dose-dependent responses: 1.57 g/dL (100 mg), 2.22 g/dL (150 mg), and 2.92 g/dL (200 mg) after 6 weeks 4

Contraindications and Precautions

Absolute Contraindications

While specific contraindications for desidustat are not explicitly detailed in the available evidence, active infections warrant withholding treatment, as patients with active infections were excluded from clinical trials 5

Safety Considerations

• Cardiovascular safety: As with all HIF-prolyl hydroxylase inhibitors, cardiovascular outcomes remain a concern, though desidustat demonstrated comparable safety to ESAs in phase 3 trials 3, 6
• The drug was well-tolerated with no deaths or serious adverse events reported in phase 2 studies 4
• Treatment-emergent adverse events were mild and comparable to active comparators (darbepoetin, epoetin alfa) 2, 3

Monitoring Parameters

Hemoglobin Monitoring

• Baseline hemoglobin assessment required before initiation 2, 3
• Monitor hemoglobin levels regularly during the evaluation period (weeks 16-24) to assess response 2, 3
• Target hemoglobin range: 10-12 g/dL 3
• Avoid excessive hemoglobin increases that exceed target range 7

Iron Metabolism Monitoring

• Hepcidin levels: Desidustat significantly reduces hepcidin compared to darbepoetin (p=0.0032 at week 12, p=0.0016 at week 24) 2
• Lipid profile: Monitor LDL cholesterol, as desidustat showed statistically significant changes from baseline to week 24 (p=0.0269) 2
• VEGF levels: While monitored in trials, changes were not statistically significant between desidustat and comparators 2

Additional Safety Monitoring

• Vital signs and ECG parameters: No significant changes were observed in clinical trials, but routine monitoring is prudent 4
• Renal function: Continue monitoring kidney function as part of standard CKD care 7
• Infection surveillance: Given the theoretical concerns with HIF-PHIs and iron metabolism affecting immune response, monitor for signs of infection 5

Clinical Context and Comparative Effectiveness

Position in Treatment Algorithm

• Desidustat demonstrated non-inferiority to darbepoetin in non-dialysis CKD (difference: 0.11 g/dL; 95% CI: -0.12,0.34) 2
• Desidustat showed non-inferiority to epoetin alfa in dialysis-dependent CKD (difference: 0.14 g/dL; 95% CI: -0.13,0.42) 3
• However, ESAs remain the preferred first-line therapy according to recent KDIGO 2026 guidelines due to persisting cardiovascular safety concerns with HIF-PHIs 6, 7

Advantages Over ESAs

• Oral administration versus subcutaneous injection, improving patient convenience 1, 8
• Superior hemoglobin response rates in non-dialysis CKD: 77.78% vs 68.48% with darbepoetin (p=0.0181) 2
• Improved iron metabolism: Reduces hepcidin levels, potentially improving iron utilization 2

Important Caveats

• Currently approved only in India; not approved in the US or Europe 1, 6
• Long-term cardiovascular safety data remain limited compared to established ESAs 6, 7
• Network meta-analyses suggest roxadustat may have stronger hemoglobin efficacy among HIF-PHIs, but also higher adverse event rates 9
• The KDIGO 2026 guideline emphasizes individualized timing and type of treatment based on comprehensive evaluation of anemia causes beyond erythropoietin insufficiency 6, 7